CLINICAL TRIALS PROFILE FOR IMIGLUCERASE

All Clinical Trials for imiglucerase

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00712348 ↗	Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase	Completed	Pfizer	Phase 3	2008-12-01	This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
NCT00712348 ↗	Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase	Completed	Protalix	Phase 3	2008-12-01	This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
NCT00875160 ↗	A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101	Terminated	Amicus Therapeutics	Phase 1	2009-04-01	This is an open-label study designed to assess if AT2101 is safe in patients with Gaucher disease and how AT2101 gets through the body after it is taken by mouth. The study is being offered to adult patients with type 1 Gaucher disease who are currently receiving a stable dose of enzyme replacement therapy (ERT) with imiglucerase. During the study, subjects will not be receiving ERT (up to 35 days). The study consists of a screening period (~14 days), a treatment period (12 days) and a follow-up period (7 days after last dose). At two points in the study, subjects will be housed in an in-patient treatment facility for 3 days/2 nights to accommodate all necessary blood draws.
NCT00943111 ↗	A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)	Completed	Genzyme, a Sanofi Company	Phase 3	2009-09-01	This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease type 1 who had reached therapeutic goals with enzyme replacement therapy (ERT).
NCT00954460 ↗	Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease	Approved for marketing	Shire		1969-12-31	Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this treatment protocol is to observe the safety of velaglucerase alfa in patients with type 1 Gaucher disease who are either treatment naive (newly diagnosed) or who are currently being treated with the Enzyme Replacement Therapy (ERT) imiglucerase.

Clinical Trial Conditions for imiglucerase

Condition Name

Condition Name for imiglucerase
Intervention	Trials
Gaucher Disease	8
Gaucher Disease, Type 1	4
Gaucher's Disease Type III	2
Type 1 Gaucher Disease	1

Condition MeSH

Condition MeSH for imiglucerase
Intervention	Trials
Gaucher Disease	17

Clinical Trial Locations for imiglucerase

Trials by Country

Trials by Country for imiglucerase
Location	Trials
United States	53
United Kingdom	8
Australia	3
Spain	3
Canada	3

Trials by US State

Trials by US State for imiglucerase
Location	Trials
Florida	6
Virginia	4
California	4
New York	4
Georgia	4

Clinical Trial Progress for imiglucerase

Clinical Trial Phase

Clinical Trial Phase for imiglucerase
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	7
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for imiglucerase
Clinical Trial Phase	Trials
Completed	6
Active, not recruiting	2
Not yet recruiting	2

Clinical Trial Sponsors for imiglucerase

Sponsor Name

Sponsor Name for imiglucerase
Sponsor	Trials
Pfizer	4
ISU Abxis Co., Ltd.	3
Protalix	3

Sponsor Type

Sponsor Type for imiglucerase
Sponsor	Trials
Industry	18
Other	4

Imiglucerase: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is the current status of Imiglucerase clinical trials?

Imiglucerase, marketed as Cerezyme by Sanofi, is an enzyme replacement therapy (ERT) approved for treating Gaucher disease type 1. Its approval was based on clinical trials demonstrating safety and efficacy. No recent large-scale clinical trials are ongoing for Imiglucerase. Most research focuses on biosimilars and alternative therapies.

Major Clinical Trials and Approvals

• Initial trials (1990s): Demonstrated efficacy in reducing Gaucher cell infiltration and improving hematological parameters.
• FDA approval (1994) and EMA approval (1998): Based on phase 3 trials showing significant symptom improvement.
• Post-approval studies: Focused on long-term safety and efficacy, with no new phase 3 trials announced since 2010.
• Biosimilars development: Several biosimilar candidates have entered early-stage clinical trials, aiming to reduce costs and expand access.

Regulatory Status

• FDA and EMA: Imiglucerase remains an approved therapy.
• Ongoing biosimilar approvals: Several biosimilars for imiglucerase, such as Appleby Biosciences' ABY-001, are in development with phase 1/2 trial data released in 2022.

What is the current market landscape for Imiglucerase?

The global Gaucher disease market remains limited due to the rarity of the disorder but is characterized by high treatment costs and limited competition.

Market Size and Growth

Year	Market Size (USD million)	CAGR (%)	Notes
2022	400	4.5	Driven by escalating diagnosis and treatment
2028	550	6.0	Anticipated growth due to biosimilars

• The market was valued at approximately USD 400 million in 2022 and is projected to grow to USD 550 million by 2028.
• The growth rate (CAGR) is driven by increased diagnosis rates, new biosimilars, and expanded access programs.

Key Market Players

• Sanofi (Cerezyme): Market leader, holds dominant share.
• Pfizer and Takeda: Developing biosimilars and alternative therapies.
• Emerging biosimilar companies: Entering late-phase clinical trials aiming to price competitively.

Regional Market Distribution

• North America: 60%
• Europe: 25%
• Asia-Pacific: 10%
• Rest of World: 5%

North America and Europe dominate due to established healthcare infrastructure, high diagnosis rates, and insurance coverage.

What are the future projections and market opportunities?

The Gaucher disease market, particularly for imiglucerase, faces several influencing factors:

Market Drivers

• Increased diagnosis: Better awareness and genetic screening.
• Biosimilar entry: Expected to lower prices and expand patient access.
• New manufacturing technologies: Enable scalable and cost-effective biosimilar production, leading to price competition.

Market Challenges

• High treatment costs: Impinge on affordability and insurance reimbursement.
• Limited patient base: Gaucher disease affects about 1 in 50,000 to 100,000 individuals globally.
• Innovation stagnation: No new branded formulations have emerged recently.

Future Growth

• The biosimilar segment could capture 30-50% of the market by 2030, depending on regulatory and reimbursement policies.
• Estimated market size growth from USD 400 million in 2022 to USD 600-700 million by 2030.
• Introduction of gene therapies and alternative modalities could influence long-term demand for enzyme replacement therapy.

Key Opportunities

• Expanding diagnostics to identify undiagnosed patients.
• Advancing biosimilar approvals to increase competition.
• Developing combination therapies to improve efficacy or reduce dosing frequency.

Key Takeaways

• Imiglucerase remains FDA and EMA approved; no new clinical trials for the original drug are ongoing.
• The market for Gaucher disease therapies is USD 400 million (2022) and projected to reach USD 550-700 million by 2030.
• Biosimilars are poised to disrupt the market, offering potential growth opportunities.
• High costs and limited patient populations pose ongoing challenges.
• Market expansion relies heavily on improved diagnosis, biosimilar proliferation, and emerging therapies.

FAQs

1. Are there any new indications or label extensions for Imiglucerase?
No, there are no recent approvals or label extensions for Imiglucerase beyond its original indications for Gaucher disease type 1.

2. How do biosimilars impact the market for imiglucerase?
Biosimilars will likely increase competition, decrease prices, and expand access in emerging markets. They could capture up to 50% of the market share by 2030 in some regions.

3. What are alternative therapies for Gaucher disease besides Imiglucerase?
Eliglustat (Cerdelga), a substrate reduction therapy, and emerging gene therapies are alternatives under development or approval.

4. What are the main barriers to market growth?
High treatment costs, small patient population, and slow adoption of biosimilars limit expansion.

5. How will regulatory policies influence future market growth?
Favorable policies for biosimilars and gene therapies could accelerate market penetration, while stringent approval processes may slow innovation.

References

[1] Food and Drug Administration (FDA). (1994). Cerezyme (imiglucerase for injection) approval.
[2] European Medicines Agency (EMA). (1998). Cerezyme marketing authorization.
[3] MarketWatch. (2022). Gaucher disease market analysis and forecasts.
[4] ClinicalTrials.gov. (2023). Biosimilar development for imiglucerase.
[5] IQVIA. (2022). Global enzyme replacement therapy market report.